Literature DB >> 7028069

Failure of specific active immunotherapy in lung cancer.

R G Souter, P G Gill, A J Gunning, P J Morris.   

Abstract

A randomized trial comparing routine follow-up with a treatment regimen aimed at increasing specific anti-tumour immunity has been carried out in 95 patients after total surgical excision of lung cancer (not small-cell). Treatment consisted of inoculation with an autologous irradiated suspension of tumour cells combined with a small dose of C. parvum given intradermally during convalescence. Although treatment was associated with virtually no side effects, there has been no apparent benefit and input to the trial has now stopped.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7028069      PMCID: PMC2010816          DOI: 10.1038/bjc.1981.217

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Sinus histiocytosis of lymph nodes in cancer.

Authors:  M M BLACK; F D SPEER
Journal:  Surg Gynecol Obstet       Date:  1958-02

2.  Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.

Authors:  F R Eilber; D L Morton; E C Holmes; F C Sparks; K P Ramming
Journal:  N Engl J Med       Date:  1976-01-29       Impact factor: 91.245

3.  Prognosis of early bronchogenic carcinoma. Survival curves of 451 patients after resection of lung cancer in relation to the results of pre-operative tuberculin skin test.

Authors:  L Israel; J Mugica; P Chahinian
Journal:  Biomedicine       Date:  1973-02-10

4.  Increased incidence of lung metastases following treatment of rats bearing hepatomas with irradiated tumour cells and the benefical effect of Corynebacterium parvum in this system.

Authors:  J Proctor; C M Rudenstam; P Alexander
Journal:  Biomedicine       Date:  1973-06-20

5.  The presence of delayed hypersensitivity reactions in patients toward cellular extracts of their malignant tumors. 2. A correlation between the histologic picture of lymphocyte infiltration of the tumor stroma, the presence of such a reaction, and a discussion of the significance of this phenomenon.

Authors:  T H Stewart
Journal:  Cancer       Date:  1969-06       Impact factor: 6.860

6.  Corynebacterium parvum as a therapeutic antitumor agent in mice. II. Local injection.

Authors:  M T Scott
Journal:  J Natl Cancer Inst       Date:  1974-09       Impact factor: 13.506

7.  Regional immunotherapy of lung cancer with intrapleural B.C.G.

Authors:  M F McKneally; C Maver; H W Kausel
Journal:  Lancet       Date:  1976-02-21       Impact factor: 79.321

8.  5-year follow-up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus.

Authors:  H Stott; R J Stephens; W Fox; D C Roy
Journal:  Br J Cancer       Date:  1976-08       Impact factor: 7.640

9.  Active specific immunotherapy of mouse methylcholanthrene induced tumours with Corynebacterium parvum and irradiated tumour cells.

Authors:  R Bomford
Journal:  Br J Cancer       Date:  1975-11       Impact factor: 7.640

10.  Effect of C. Parvum on immunization with irradiated tumour cells.

Authors:  M F Woodruff; A Ghaffar; N Dunbar; V L Whitehead
Journal:  Br J Cancer       Date:  1976-05       Impact factor: 7.640

View more
  4 in total

1.  A phase-II trial of Corynebacterium parvum as adjuvant to surgery in the treatment of operable lung cancer.

Authors:  M Woodruff; P Walbaum
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

2.  Corynebacterium parvum and metastatic breast cancer.

Authors:  C M Haskell; G P Sarna; P Y Liu
Journal:  Br J Cancer       Date:  1982-05       Impact factor: 7.640

Review 3.  Immunotherapy in lung cancer.

Authors:  M Al-Moundhri; M O'Brien; B E Souberbielle
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

4.  Propionibacterium acnes Augments Antitumor, Anti-Angiogenesis and Immunomodulatory Effects of Melatonin on Breast Cancer Implanted in Mice.

Authors:  Wamidh H Talib; Suhair Saleh
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.